Vesivax subunit vaccine for avian infectious bronchitis virus
VesiVax-IBV is a subunit vaccine leveraging immunogenic liposomal delivery to combat avian infectious bronchitis virus. Designed for scalable production, it co-delivers adjuvant and antigen, enhancing immune response in poultry.
Overview
The VesiVax-IBV vaccine represents a significant advancement in the fight against avian infectious bronchitis virus (IBV), a prevalent disease affecting poultry. Utilizing a subunit approach, this vaccine employs a proprietary liposomal formulation to effectively co-deliver a potent adjuvant and a cross-protective antigen. The innovation lies in its ability to be easily scaled for production, addressing both efficacy and manufacturing efficiency. With 30 years of expertise backing its development, VesiVax-IBV promises to enhance immunity in poultry, potentially reducing the impact of IBV outbreaks.
Technical specifications
- Liposomal formulation: Optimized for delivering a wide range of antigens and adjuvants, including peptides, proteins, and virus-like particles.
- Cross-protective antigen: Specifically targets IBV, providing broad immunity.
- Scalable production: Designed for easy manufacturing, facilitating rapid deployment in poultry populations.
- Validation process: Includes in vitro characterization of physicochemical properties and in vivo testing in poultry to measure immune response, such as serum and virus neutralization titers.
Technology readiness level
The VesiVax-IBV vaccine is currently at Technology Readiness Level 6, indicating that it has been demonstrated in a relevant environment, with ongoing validation including candidate formulation testing and immune response evaluation in poultry models.
About Molecular Express, Inc.
Molecular Express, Inc. is a biotechnology company that specializes in advanced formulation services to accelerate the development of vaccines, therapeutics, and small molecule drugs. The company utilizes its proprietary Molecular GPS™ and VesiVax® platforms for targeted drug delivery, nanoparticle design, and engineering. By leveraging these advanced delivery systems, the company provides essential support for protein processing, production, and rigorous analytical testing. Its expertise enables researchers to conjugate target molecules and stabilize compounds, ensuring they meet the required quality standards for preclinical and clinical development. Molecular Express, Inc. operates as a key research and development subsidiary of Molecular GPS Technologies™, collaborating with academic institutions and government agencies to bring innovative scientific research to market.
The company plays a vital role in life sciences by helping partners secure funding and grants to translate groundbreaking discoveries into viable clinical solutions. By providing efficient, scalable protein production and customized formulation services, it addresses significant bottlenecks in therapeutic development, such as supply constraints and manufacturing complexity. Through its work with the NIH and other organizations, Molecular Express contributes to public health by developing specialized treatments, including synthetic lung surfactants and immunomodulatory adjuvants. This collaborative, research-driven approach allows the company to support a wide range of projects, from oncology and infectious disease vaccines to novel medical imaging agents and addiction therapies, ultimately bridging the gap between bench-top research and real-world medical applications.
delivered to your inbox.